Gianni Pezzoli

List of Publications by Year
in descending order

211 papers	13,270 citations	22153 59 h-index	28297 105 g-index
211 all docs	211 docs citations	211 times ranked	15433 citing authors

#	Article	IF	Citations
1	Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature, 2011, 476, 224-227.	27.8	941
2	Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease. New England Journal of Medicine, 2007, 356, 39-46.	27.0	824
3	T1 and T2 in the Brain of Healthy Subjects, Patients with Parkinson Disease, and Patients with Multiple System Atrophy: Relation to Iron Content. Radiology, 1999, 211, 489-495.	7.3	314
4	Survival and dementia in <scp>GBA</scp>â€associated Parkinson's disease: <scp>T</scp>he mutation matters. Annals of Neurology, 2016, 80, 662-673.	5.3	312
5	Clinical Correlations With Lewy Body Pathology inLRRK2-Related Parkinson Disease. JAMA Neurology, 2015, 72, 100.	9.0	272
6	Probiotics and prebiotic fiber for constipation associated with Parkinson disease. Neurology, 2016, 87, 1274-1280.	1.1	264
7	Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism. Movement Disorders, 2019, 34, 396-405.	3.9	252
8	The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain, 2014, 137, 2731-2742.	7.6	251
9	Duodenal levodopa infusion for advanced Parkinson's disease: 12â€month treatment outcome. Movement Disorders, 2007, 22, 1145-1149.	3.9	241
10	Exposure to pesticides or solvents and risk of Parkinson disease. Neurology, 2013, 80, 2035-2041.	1.1	238
11	Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. European Journal of Human Genetics, 2005, 13, 748-752.	2.8	197
12	Major nutritional issues in the management of Parkinson's disease. Movement Disorders, 2009, 24, 1881-1892.	3.9	183
13	Diabetes and Risk of Parkinsonâ€™s Disease. Diabetes Care, 2011, 34, 2614-2623.	8.6	181
14	Parkinsonâ€™s disease in GTP cyclohydrolase 1 mutation carriers. Brain, 2014, 137, 2480-2492.	7.6	169
15	Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinsonâ€™s disease. Npj Parkinson's Disease, 2018, 4, 11.	5.3	169
16	Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Annals of Neurology, 2011, 70, 964-973.	5.3	168
17	Mutations in the GIGYF2 (TNRC15) Gene at the PARK11 Locus in Familial Parkinson Disease. American Journal of Human Genetics, 2008, 82, 822-833.	6.2	164
18	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. European Journal of Human Genetics, 2006, 14, 322-331.	2.8	152

#	Article	IF	Citations
19	Influence of Heterozygosity for Parkin Mutation on Onset Age in Familial Parkinson Disease. Archives of Neurology, 2006, 63, 826.	4.5	147
20	Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease. Frontiers in Aging Neuroscience, 2016, 8, 196.	3.4	146
21	Impulsivity and compulsivity in drugâ€naÃ¯ve patients with Parkinson's disease. Movement Disorders, 2011, 26, 464-468.	3.9	139
22	Intensive Rehabilitation Treatment in Early Parkinsonâ€™s Disease. Neurorehabilitation and Neural Repair, 2015, 29, 123-131.	2.9	137
23	Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiology of Disease, 2010, 39, 98-104.	4.4	136
24	Body weight gain rate in patients with Parkinson's disease and deep brain stimulation. Movement Disorders, 2003, 18, 1337-1340.	3.9	132
25	The relationship between impulsivity and impulse control disorders in Parkinson's disease. Movement Disorders, 2008, 23, 411-415.	3.9	131
26	<scp>COVID</scp>â€19 in Parkinsonâ€™s Disease Patients Living in Lombardy, Italy. Movement Disorders, 2020, 35, 1089-1093.	3.9	129
27	Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease. Archives of Neurology, 2008, 65, 1604-11.	4.5	127
28	Validation of the Italian version of the Movement Disorder Societyâ€"Unified Parkinsonâ€™s Disease Rating Scale. Neurological Sciences, 2013, 34, 683-687.	1.9	123
29	Intensive Rehabilitation Increases BDNF Serum Levels in Parkinsonian Patients. Neurorehabilitation and Neural Repair, 2014, 28, 163-168.	2.9	118
30	A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. Journal of Neurology, 2011, 258, 579-585.	3.6	113
31	Effect of nerve growth factor in adrenal autografts in parkinsonism. Annals of Neurology, 1990, 27, 341-342.	5.3	109
32	The Neuromelanin of Human Substantia Nigra: Physiological and Pathogenic Aspects. Pigment Cell & Melanoma Research, 2004, 17, 610-617.	3.6	109
33	Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: A path modeling analysis. Movement Disorders, 2011, 26, 225-233.	3.9	109
34	LRRK2 G2019S mutation and Parkinson's disease: A clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism and Related Disorders, 2006, 12, 410-419.	2.2	106
35	Genomewide association study for onset age in Parkinson disease. BMC Medical Genetics, 2009, 10, 98.	2.1	104
36	Mitochondrial dysfunction in Parkinsonian mesenchymal stem cells impairs differentiation. Redox Biology, 2018, 14, 474-484.	9.0	104

#	Article	IF	Citations
37	Remote control of induced dopaminergic neurons in parkinsonian rats. Journal of Clinical Investigation, 2014, 124, 3215-3229.	8.2	104
38	Microtubule Alterations Occur Early in Experimental Parkinsonism and The Microtubule Stabilizer Epothilone D Is Neuroprotective. Scientific Reports, 2013, 3, 1837.	3.3	103
39	Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life. Movement Disorders, 2006, 21, 1119-1122.	3.9	101
40	Prevalence of fatigue in Parkinson disease and its clinical correlates. Neurology, 2014, 83, 215-220.	1.1	98
41	Freezing of gait in Parkinsonâ€™s disease reflects a sudden derangement of locomotor network dynamics. Brain, 2019, 142, 2037-2050.	7.6	96
42	Swallowing disturbances in Parkinson's disease: A multivariate analysis of contributing factors. Parkinsonism and Related Disorders, 2014, 20, 1382-1387.	2.2	93
43	Natural history of motor symptoms in Parkinsonâ€™s disease and the long-duration response to levodopa. Brain, 2020, 143, 2490-2501.	7.6	87
44	Tcâ€99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Movement Disorders, 2002, 17, 1265-1270.	3.9	86
45	Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. PLoS ONE, 2011, 6, e18301.	2.5	84
46	Increased urinary indoxyl sulfate (indican): New insights into gut dysbiosis in Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 389-393.	2.2	82
47	Rapid Generation of Functional Dopaminergic Neurons From Human Induced Pluripotent Stem Cells Through a Single-Step Procedure Using Cell Lineage Transcription Factors. Stem Cells Translational Medicine, 2013, 2, 473-479.	3.3	81
48	Imaging essential tremor. Movement Disorders, 2010, 25, 679-686.	3.9	80
49	Î±-Synuclein is a Novel Microtubule Dynamase. Scientific Reports, 2016, 6, 33289.	3.3	79
50	Mucuna pruriens in Parkinson disease. Neurology, 2017, 89, 432-438.	1.1	79
51	PINK1heterozygous rare variants: prevalence, significance and phenotypic spectrum. Human Mutation, 2008, 29, 565-565.	2.5	74
52	The Beneficial Role of Intensive Exercise on Parkinson Disease Progression. American Journal of Physical Medicine and Rehabilitation, 2013, 92, 523-532.	1.4	74
53	Dietary habits and neurological features of Parkinson's disease patients: Implications for practice. Clinical Nutrition, 2017, 36, 1054-1061.	5.0	74
54	Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine. Movement Disorders, 2019, 34, 9-21.	3.9	73

#	Article	IF	Citations
55	Striatal dopamine transporter abnormalities in patients with essential tremor. Nuclear Medicine Communications, 2008, 29, 349-353.	1.1	69
56	Lowâ€protein and proteinâ€redistribution diets for Parkinson's disease patients with motor fluctuations: A systematic review. Movement Disorders, 2010, 25, 2021-2034.	3.9	69
57	Whole gene deletion and splicing mutations expand thePINK1 genotypic spectrum. Human Mutation, 2007, 28, 98-98.	2.5	66
58	Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy. European Radiology, 2017, 27, 2665-2675.	4.5	66
59	Glucocerebrosidase mutations in primary parkinsonism. Parkinsonism and Related Disorders, 2014, 20, 1215-1220.	2.2	63
60	Predictors of COVID-19 outcome in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 78, 134-137.	2.2	63
61	Brain networks underlining verbal fluency decline during STN-DBS in Parkinson's disease: An ECD-SPECT study. Parkinsonism and Related Disorders, 2007, 13, 290-294.	2.2	61
62	Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy. Journal of Neural Transmission, 2016, 123, 1435-1442.	2.8	61
63	Cyclin-G-associated kinase modifies Â-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. Human Molecular Genetics, 2011, 20, 1478-1487.	2.9	60
64	DNAJC12 and dopaâ€responsive nonprogressive parkinsonism. Annals of Neurology, 2017, 82, 640-646.	5.3	60
65	[123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. NeuroReport, 2007, 18, 1499-1502.	1.2	59
66	Asymmetry and freezing of gait in parkinsonian patients. Journal of Neurology, 2013, 260, 71-76.	3.6	59
67	Dietary habits in Parkinson's disease: Adherence to Mediterranean diet. Parkinsonism and Related Disorders, 2017, 42, 40-46.	2.2	58
68	Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 311-318.	1.9	57
69	Vitamin D supplementation and outcomes in coronavirus disease 2019 (COVID-19) patients from the outbreak area of Lombardy, Italy. Nutrition, 2021, 82, 111055.	2.4	57
70	Parkinson's disease beyond 20â€...years. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 849-855.	1.9	55
71	Levodopa in Parkinson's disease: from the past to the future. Expert Opinion on Pharmacotherapy, 2010, 11, 627-635.	1.8	54
72	Sarcopenia and Dynapenia in Patients With Parkinsonism. Journal of the American Medical Directors Association, 2016, 17, 640-646.	2.5	53

#	Article	IF	Citations
73	Elemental mapping of Neuromelanin organelles of human Substantia Nigra: correlative ultrastructural and chemical analysis by analytical transmission electron microscopy and nanoâ€secondary ion mass spectrometry. Journal of Neurochemistry, 2016, 138, 339-353.	3.9	53
74	Dementia in Parkinson's disease: Is male gender a risk factor?. Parkinsonism and Related Disorders, 2016, 26, 67-72.	2.2	52
75	Efficacy of rasagiline and selegiline in Parkinsonâ€™s disease: a head-to-head 3-year retrospective caseâ€“control study. Journal of Neurology, 2017, 264, 1254-1263.	3.6	52
76	SNCA and MAPT genes: Independent and joint effects in Parkinson disease in the Italian population. Parkinsonism and Related Disorders, 2012, 18, 257-262.	2.2	51
77	A role for locus coeruleus in Parkinson tremor. Frontiers in Human Neuroscience, 2011, 5, 179.	2.0	51
78	Thin Section MR Study of the Basal Ganglia in the Differential Diagnosis Between Striatonigral Degeneration and Parkinson Disease. Journal of Computer Assisted Tomography, 2002, 26, 266-271.	0.9	49
79	Cognitive status of patients with Parkinsonâ€™s disease and pathological gambling. Journal of Neurology, 2010, 257, 247-252.	3.6	49
80	Kinâ€cohort analysis of LRRK2â€G2019S penetrance in Parkinson's disease. Movement Disorders, 2011, 26, 2144-2145.	3.9	49
81	Mini Nutritional Assessment in patients with Parkinson's disease: correlation between worsening of the malnutrition and increasing number of disease-years. Nutritional Neuroscience, 2008, 11, 128-134.	3.1	48
82	Extradural motor cortex stimulation in Parkinson's disease. Movement Disorders, 2007, 22, 111-114.	3.9	46
83	Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease. BMC Neurology, 2011, 11, 88.	1.8	46
84	Intensive Rehabilitation Enhances Lymphocyte BDNF-TrkB Signaling in Patients With Parkinsonâ€™s Disease. Neurorehabilitation and Neural Repair, 2016, 30, 411-418.	2.9	46
85	Striatal Dopaminergic Innervation Regulates Subthalamic Beta-Oscillations and Cortical-Subcortical Coupling during Movements: Preliminary Evidence in Subjects with Parkinsonâ€™s Disease. Frontiers in Human Neuroscience, 2016, 10, 611.	2.0	45
86	Rehabilitation in progressive supranuclear palsy: Effectiveness of two multidisciplinary treatments. PLoS ONE, 2017, 12, e0170927.	2.5	45
87	Special low-protein foods ameliorate postprandialoff in patients with advanced Parkinson's disease. Movement Disorders, 2006, 21, 1682-1687.	3.9	44
88	Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile. Journal of the Neurological Sciences, 2016, 365, 175-180.	0.6	44
89	Microtubule Destabilization Is Shared by Genetic and Idiopathic Parkinsonâ€™s Disease Patient Fibroblasts. PLoS ONE, 2012, 7, e37467.	2.5	43
90	Nutritional risk and gastrointestinal dysautonomia symptoms in Parkinson's disease outpatients hospitalised on a scheduled basis. British Journal of Nutrition, 2013, 110, 347-353.	2.3	43

#	Article	IF	Citations
91	Parkin absence accelerates microtubule aging in dopaminergic neurons. Neurobiology of Aging, 2018, 61, 66-74.	3.1	43
92	Parkin analysis in early onset Parkinson's disease. Parkinsonism and Related Disorders, 2008, 14, 326-333.	2.2	42
93	Striatal dopamine transporter binding in Parkinson's disease associated with theLRRK2 Gly2019Ser mutation. Movement Disorders, 2006, 21, 1144-1147.	3.9	41
94	Low cardiometabolic risk in Parkinson's disease is independent of nutritional status, body composition and fat distribution. Clinical Nutrition, 2012, 31, 699-704.	5.0	41
95	Reproductive factors and clinical features of Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 1094-1099.	2.2	41
96	Finding a new therapeutic approach for no-option Parkinsonisms: mesenchymal stromal cells for progressive supranuclear palsy. Journal of Translational Medicine, 2016, 14, 127.	4.4	41
97	Î±-Synuclein oligomers in skin biopsy of idiopathic and monozygotic twin patients with Parkinsonâ€™s disease. Brain, 2020, 143, 920-931.	7.6	41
98	Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson's disease: A prospective case-control study. Clinical Neurology and Neurosurgery, 2009, 111, 140-146.	1.4	40
99	Psychiatric symptoms in Parkinsonâ€™s disease assessed with the SCL-90R self-reported questionnaire. Neurological Sciences, 2010, 31, 35-40.	1.9	40
100	LRRK2 mutations in Parkinson's disease: Confirmation of a gender effect in the Italian population. Parkinsonism and Related Disorders, 2014, 20, 911-914.	2.2	40
101	Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study. Parkinsonism and Related Disorders, 2018, 49, 60-66.	2.2	39
102	Diabetes and risk of Parkinson's disease. Movement Disorders, 2013, 28, 257-261.	3.9	38
103	Phase matters: A role for the subthalamic network during gait. PLoS ONE, 2018, 13, e0198691.	2.5	38
104	Protein intake in Parkinsonian patients using the EPIC food frequency questionnaire. Movement Disorders, 2006, 21, 1229-1231.	3.9	37
105	The SPID-GBA study. Neurology: Genetics, 2020, 6, e523.	1.9	37
106	n-Hexane induces Parkinsonism in rodents. Brain Research, 1990, 531, 355-357.	2.2	36
107	Î±-Synuclein multiplication analysis in Italian familial Parkinson disease. Parkinsonism and Related Disorders, 2010, 16, 228-231.	2.2	36
108	Longâ€term cognitive followâ€up of Parkinson's disease patients with impulse control disorders. Movement Disorders, 2015, 30, 696-704.	3.9	35

#	Article	IF	Citations
109	Excitability of the supplementary motor area in Parkinson's disease depends on subcortical damage. Brain Stimulation, 2019, 12, 152-160.	1.6	35
110	Replication of association between ELAVL4 and Parkinson disease: the GenePD study. Human Genetics, 2008, 124, 95-99.	3.8	34
111	Screen for Excess FMR1 Premutation Alleles Among Males With Parkinsonism. Archives of Neurology, 2007, 64, 1002.	4.5	33
112	Increased oxidative stress in lymphocytes from untreated Parkinson's disease patients. Parkinsonism and Related Disorders, 2009, 15, 327-328.	2.2	32
113	Dopaminergic Striatal Innervation Predicts Interlimb Transfer of a Visuomotor Skill. Journal of Neuroscience, 2011, 31, 14458-14462.	3.6	32
114	Factors influencing psychological well-being in patients with Parkinsonâ€™s disease. PLoS ONE, 2017, 12, e0189682.	2.5	32
115	The LRRK2 Variant E193K Prevents Mitochondrial Fission Upon MPP+ Treatment by Altering LRRK2 Binding to DRP1. Frontiers in Molecular Neuroscience, 2018, 11, 64.	2.9	32
116	Gait Initiation in Parkinsonâ€™s Disease: Impact of Dopamine Depletion and Initial Stance Condition. Frontiers in Bioengineering and Biotechnology, 2020, 8, 137.	4.1	32
117	Mechanical Energy Recovery during Walking in Patients with Parkinson Disease. PLoS ONE, 2016, 11, e0156420.	2.5	32
118	Effects of mechanical stimulation of the feet on gait and cardiovascular autonomic control in Parkinson's disease. Journal of Applied Physiology, 2014, 116, 495-503.	2.5	31
119	Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study. Journal of Translational Medicine, 2014, 12, 14.	4.4	30
120	Muscle-targeted nutritional support for rehabilitation in patients with parkinsonian syndrome. Neurology, 2019, 93, e485-e496.	1.1	30
121	Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegeneration. Movement Disorders, 2006, 21, 417-418.	3.9	28
122	Monitoring subthalamic oscillations for 24 hours in a freely moving Parkinson's disease patient. Movement Disorders, 2019, 34, 757-759.	3.9	28
123	Screening for the Presence of FMR1 Premutation Alleles in Women With Parkinsonism. Archives of Neurology, 2009, 66, 244-9.	4.5	27
124	Does Gut Microbiota Influence the Course of Parkinsonâ€™s Disease? A 3-Year Prospective Exploratory Study in de novo Patients. Journal of Parkinson's Disease, 2021, 11, 159-170.	2.8	27
125	Tryptophan hydroxylase type 2 variants modulate severity and outcome of addictive behaviors in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 29, 96-103.	2.2	26
126	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	5.3	26

#	Article	IF	Citations
127	Role of an electronic armband in motor function monitoring in patients with Parkinson's disease. Nutrition, 2010, 26, 240-242.	2.4	25
128	Neuronal microtubules and proteins linked to Parkinsonâ€™s disease: a relevant interaction?. Biological Chemistry, 2019, 400, 1099-1112.	2.5	25
129	Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease. Neurology, 2022, 99, .	1.1	25
130	A voxel-based PET study of dopamine transporters in Parkinson's disease: Relevance of age at onset. Neurobiology of Disease, 2008, 31, 102-109.	4.4	24
131	HFE gene mutations in a population of Italian Parkinson's disease patients. Parkinsonism and Related Disorders, 2008, 14, 426-430.	2.2	24
132	Screening LRRK2 gene mutations in patients with Parkinsonâ€™s disease in Ghana. Journal of Neurology, 2012, 259, 569-570.	3.6	24
133	Cardiometabolic factors and disease duration in patients with Parkinsonâ€™s disease. Nutrition, 2013, 29, 1331-1335.	2.4	24
134	Short- and Long-Term Efficacy of Intensive Rehabilitation Treatment on Balance and Gait in Parkinsonian Patients: A Preliminary Study with a 1-Year Followup. Parkinson's Disease, 2013, 2013, 1-5.	1.1	24
135	Linking microtubules to Parkinson's disease: the case of parkin. Biochemical Society Transactions, 2015, 43, 292-296.	3.4	24
136	Evaluating psychiatric symptoms in Parkinson's Disease by a clinimetric analysis of the Hopkins Symptom Checklist (SCL-90-R). Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 131-137.	4.8	24
137	Differences in Muscle Strength in Parkinsonian Patients Affected on the Right and Left Side. PLoS ONE, 2015, 10, e0121251.	2.5	23
138	Lewy body pathology and typical Parkinson disease in a patient with a heterozygous (R275W) mutation in the Parkin gene (PARK2). Acta Neuropathologica, 2012, 123, 901-903.	7.7	22
139	Novel DYT11 gene mutation in patients without dopaminergic deficit (SWEDD) screened for dystonia. Neurology, 2014, 83, 1155-1162.	1.1	22
140	Sit-to-walk performance in Parkinson's disease: A comparison between faller and non-faller patients. Clinical Biomechanics, 2019, 63, 140-146.	1.2	22
141	Nutritional characterisation of Zambian Moringa oleifera: acceptability and safety of short-term daily supplementation in a group of malnourished girls. International Journal of Food Sciences and Nutrition, 2019, 70, 107-115.	2.8	21
142	Gait initiation in progressive supranuclear palsy: brain metabolic correlates. NeuroImage: Clinical, 2020, 28, 102408.	2.7	21
143	Controlled-protein dietary regimens for Parkinson's disease. Nutritional Neuroscience, 2010, 13, 29-32.	3.1	20
144	An exome study of Parkinsonâ€™s disease in Sardinia, a Mediterranean genetic isolate. Neurogenetics, 2015, 16, 55-64.	1.4	20

#	Article	IF	Citations
145	Vitamin D Status and Parkinsonâ€™s Disease. Brain Sciences, 2022, 12, 790.	2.3	18
146	Diet with LPP for renal patients increases daily energy expenditure and improves motor function in Parkinsonian patients with motor fluctuations. Nutritional Neuroscience, 2007, 10, 129-135.	3.1	17
147	Regression of Cardiac Valvulopathy Related to Ergot-Derived Dopamine Agonists. Cardiovascular Therapeutics, 2011, 29, 404-410.	2.5	17
148	The Influence of Dopaminergic Striatal Innervation on Upper Limb Locomotor Synergies. PLoS ONE, 2012, 7, e51464.	2.5	17
149	Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinsonâ€™s Disease and Atypical Parkinsonisms. Frontiers in Neuroscience, 2020, 14, 624.	2.8	17
150	Role of Lysosomal Gene Variants in Modulating <scp>GBA</scp>â€Associated Parkinson's Disease Risk. Movement Disorders, 2022, 37, 1202-1210.	3.9	17
151	Mutational screening and zebrafish functional analysis of GIGYF2 as a Parkinson-disease gene. Neurobiology of Aging, 2011, 32, 1994-2005.	3.1	16
152	Reversible dopamine transporter reduction in drugâ€induced parkinsonism. Movement Disorders, 2014, 29, 575-577.	3.9	16
153	Creative Thinking, Professional Artists, and Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2016, 6, 239-246.	2.8	16
154	Could Mucuna pruriens be the answer to Parkinson's disease management in sub-Saharan Africa and other low-income countries worldwide?. Parkinsonism and Related Disorders, 2020, 73, 3-7.	2.2	16
155	The Asp620asn mutation in VPS35 is not a common cause of familial Parkinson's disease. Movement Disorders, 2012, 27, 800-801.	3.9	15
156	Cholinergic activity and levodopaâ€induced dyskinesia: a multitracer molecular imaging study. Annals of Clinical and Translational Neurology, 2017, 4, 632-639.	3.7	15
157	Iron deposition in Parkinsonisms: A Quantitative Susceptibility Mapping study in the deep grey matter. European Journal of Radiology, 2020, 133, 109394.	2.6	15
158	Milacemide increases 5-hydroxytryptamine and dopamine levels in rat brain â€” Possible mechanisms of milacemide antimyoclonic property in the p,pâ€²-DDT-induced myoclonus. Pharmacology Biochemistry and Behavior, 1989, 32, 993-1001.	2.9	14
159	Nutritional status and dietary habits in Parkinsonâ€™s disease patients in Ghana. Nutrition, 2013, 29, 470-473.	2.4	14
160	Does Cognitive Impairment Affect Rehabilitation Outcome in Parkinsonâ€™s Disease?. Frontiers in Aging Neuroscience, 2016, 8, 192.	3.4	14
161	Impaired reach-to-grasp kinematics in parkinsonian patients relates to dopamine-dependent, subthalamic beta bursts. Npj Parkinson's Disease, 2021, 7, 53.	5.3	14
162	Inhibitory control dysfunction in parkinsonian impulse control disorders. Brain, 2020, 143, 3734-3747.	7.6	13

#	Article	IF	Citations
163	VEGF Haplotypes are Associated with Increased Risk to Progressive Supranuclear Palsy and Corticobasal Syndrome. Journal of Alzheimer's Disease, 2010, 21, 87-94.	2.6	12
164	The effect of repeated administrations of granulocyte colony stimulating factor for blood stem cells mobilization in patients with progressive supranuclear palsy, corticobasal degeneration and multiple system atrophy. Clinical Neurology and Neurosurgery, 2010, 112, 65-67.	1.4	12
165	Effectiveness of an intensive rehabilitation treatment on different Parkinson's disease subtypes. NeuroRehabilitation, 2013, 33, 299-303.	1.3	12
166	Gambling behavior in Parkinson's Disease: Impulsivity, reward mechanism and cortical brain oscillations. Psychiatry Research, 2018, 270, 974-980.	3.3	12
167	Intensive Rehabilitation Treatment in Parkinsonian Patients with Dyskinesias: A Preliminary Study with 6-Month Followup. Parkinson's Disease, 2012, 2012, 1-4.	1.1	11
168	DJ1 analysis in a large cohort of Italian early onset Parkinson Disease patients. Neuroscience Letters, 2013, 557, 165-170.	2.1	11
169	LRRK2â€G2019S mutation is not associated with an increased cancer risk: A kinâ€cohort study. Movement Disorders, 2014, 29, 1325-1326.	3.9	11
170	Clinical correlates of serum 25-hydroxyvitamin D in Parkinsonâ€™s disease. Nutritional Neuroscience, 2022, 25, 1128-1136.	3.1	11
171	Cryopreservation of human fetal adrenal medullary cells. Brain Research, 1988, 454, 383-386.	2.2	10
172	Multiple system atrophy and CAG repeat length: A genetic screening of polyglutamine disease genes in Italian patients. Neuroscience Letters, 2018, 678, 37-42.	2.1	10
173	The Association between Î±-Synuclein and Î±-Tubulin in Brain Synapses. International Journal of Molecular Sciences, 2021, 22, 9153.	4.1	10
174	Astrocytes expressing Vitamin Dâ€activating enzyme identify Parkinsonâ€™s disease. CNS Neuroscience and Therapeutics, 2022, 28, 703-713.	3.9	10
175	Glycine involvement in DDT-induced myoclonus. Movement Disorders, 1988, 3, 77-87.	3.9	9
176	Cortical response to levodopa in Parkinson's disease patients with dyskinesias. European Journal of Neuroscience, 2018, 48, 2362-2373.	2.6	9
177	Brain metabolic alterations herald falls in patients with Parkinsonâ€™s disease. Annals of Clinical and Translational Neurology, 2020, 7, 579-583.	3.7	9
178	Primary Cultures of Human Caudate Nucleus. Stereotactic and Functional Neurosurgery, 1988, 51, 10-20.	1.5	8
179	Monoamine oxidase inhibitory properties of milacemide in rats. Life Sciences, 1989, 44, 1059-1066.	4.3	8
180	Multiple compulsive behaviors in multiple system atrophy: The importance of predisposition to addiction. Parkinsonism and Related Disorders, 2014, 20, 355-357.	2.2	8

#	Article	IF	Citations
181	Microtubule defects in mesenchymal stromal cells distinguish patients with Progressive Supranuclear Palsy. Journal of Cellular and Molecular Medicine, 2018, 22, 2670-2679.	3.6	8
182	The imbalance between dynamic and stable microtubules underlies neurodegeneration induced by 2,5-hexanedione. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165581.	3.8	8
183	Poly (ADP-ribose) polymerase 1 and Parkinson's disease: A study in post-mortem human brain. Neurochemistry International, 2021, 144, 104978.	3.8	8
184	Serum Adiponectin Levels in Advanced-Stage Parkinson's Disease Patients. Parkinson's Disease, 2011, 2011, 1-6.	1.1	7
185	Oral high-calorie, low-protein supplements in a Parkinson's disease patient: A case report. Movement Disorders, 2011, 26, 354-355.	3.9	7
186	Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. Journal of Neural Transmission, 2015, 122, 799-808.	2.8	7
187	Divergent Thinking in Parkinsonism: A Caseâ€“Control Study. Frontiers in Neurology, 2017, 8, 534.	2.4	7
188	Personality Traits and Cortical Activity Affect Gambling Behavior in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2018, 8, 341-352.	2.8	7
189	Pathological Gambling in Parkinson's disease: Autonomic measures supporting impaired decisionâ€making. European Journal of Neuroscience, 2019, 50, 2392-2400.	2.6	7
190	A rapid and low-cost test for screening the most common Parkinson's disease-related GBA variants. Parkinsonism and Related Disorders, 2020, 80, 138-141.	2.2	7
191	Saposin D variants are not a common cause of familial Parkinsonâ€™s disease among Italians. Brain, 2020, 143, e71-e71.	7.6	7
192	A human minisatellite hosts an alternative transcription start site for NPRL3 driving its expression in a repeat numberâ€dependent manner. Human Mutation, 2020, 41, 807-824.	2.5	6
193	Association analysis of PARP1 polymorphisms with Parkinsonâ€™s disease. Parkinsonism and Related Disorders, 2011, 17, 701-704.	2.2	5
194	Screening of LRP10 mutations in Parkinson's disease patients from Italy. Parkinsonism and Related Disorders, 2021, 89, 17-21.	2.2	5
195	Human Fetal Adrenal Medulla for Transplantation in Parkinsonian Patients. Annals of the New York Academy of Sciences, 1987, 495, 771-773.	3.8	4
196	Analysis of Nucleotide Variations in Genes of Iron Management in Patients of Parkinson's Disease and Other Movement Disorders. Parkinson's Disease, 2011, 2011, 1-6.	1.1	4
197	A focus on Rome III criteria for the assessment of constipation in Parkinson's disease. Movement Disorders, 2017, 32, 630-630.	3.9	4
198	Resting state oscillations suggest a motor component of Parkinsonâ€™s Impulse Control Disorders. Clinical Neurophysiology, 2019, 130, 2065-2075.	1.5	4

#	Article	IF	Citations
199	[123I]FP-CIT SPECT in atypical degenerative parkinsonism. Imaging in Medicine, 2012, 4, 411-421.	0.0	3
200	Meningioma with intense I¹²³ FPâ€CIT uptake. Movement Disorders, 2012, 27, 1744-1745.	3.9	3
201	The sleeve gastrectomy intervention to treat morbid obesity in a Parkinson's disease patient. Clinical Nutrition, 2013, 32, 476-478.	5.0	3
202	Later age at onset in Parkinson's disease over twenty years in an Italian tertiary clinic. Parkinsonism and Related Disorders, 2014, 20, 1181-1185.	2.2	3
203	Resting energy expenditure in Parkinsonâ€™s disease patients under dopaminergic treatment. Nutritional Neuroscience, 2022, 25, 246-255.	3.1	3
204	Endothelial progenitor cells: Cardiovascular protection in Parkinson's disease?. International Journal of Cardiology, 2015, 197, 200-202.	1.7	2
205	Reply to: Standardized 25â€Hydroxyvitamin D Measurements in Parkinsonâ€™s Disease Patients With COVIDâ€19. Movement Disorders, 2020, 35, 1498-1498.	3.9	2
206	â€˜Corrigendum to â€œIncreased Levels of Endothelial Progenitor Cells in Parkinson's Diseaseâ€• [Parkinsonism Rel Dis 17 (2011) 651â€“652]â€™. Parkinsonism and Related Disorders, 2012, 18, 807.	2.2	1
207	Proteinâ€redistribution diet in a case of tyrosine hydroxylase enzyme deficiency. Movement Disorders, 2017, 32, 794-795.	3.9	1
208	Safety and Effectiveness of Cell Therapy in Neurodegenerative Diseases: Take-Home Messages From a Pilot Feasibility Phase I Study of Progressive Supranuclear Palsy. Frontiers in Neuroscience, 2021, 15, 723227.	2.8	1
209	Corrigendum to â€œThe sleeve gastrectomy intervention to treat morbid obesity in a parkinson's disease patientâ€•[Clin Nutr 32 (3) (2013) 476â€“478]. Clinical Nutrition, 2014, 33, 928.	5.0	0
210	Author response: Muscle-targeted nutritional support for rehabilitation in patients with parkinsonian syndrome. Neurology, 2020, 95, 143-143.	1.1	0
211	The Hopkins Symptom Checklist (SCL-90-R): A Patient-Reported Outcome Measure in Parkinsonâ€™s Disease. Journal of Geriatric Psychiatry and Neurology, 2021, , 089198872110600.	2.3	0